Navigation Links
Singapore scientists discover new RNA processing pathway important in human embryonic stem cells
Date:9/9/2013

09 Sept 2013 - Scientists at A*STAR's Genome Institute of Singapore (GIS), in collaboration with their counterparts from Canada, Hong Kong and US, have discovered a protein mediator SON plays a critical role in the health and proper functioning of human embryonic stem cells (hESCs). This finding was reported on 8th September 2013 in the advanced online issue of the prestigious science journal Nature Cell Biology.

Correct expression of genes is essential for a cell to stay alive and to perform other cellular and physiological functions. During gene expression, DNA is first converted into RNA transcript and then some parts of it are removed while others are joined before the trimmed RNA transcript can be translated into proteins. This process of cutting and joining different pieces of RNA is called splicing, and the proteins that mediate splicing are known as splicing factors. Mutations in splicing factors can cause diseases such as myotonic dystrophy and cancer. Even though hESCs have been studied extensively over the last decade due to their potential to differentiate into cell-types of potential clinical applications, little is known about the role that splicing plays in the regulation of pluripotency in these cells.

Scientists at the GIS followed their previous study on a genome-wide investigation of gene functions in hESCs, which was published in Nature [Chia et al. 2010. 468(7321):316-20], and found that splicing factors, such as the protein known as SON, are key regulators of hESC maintenance.

SON was discovered to be essential for converting differentiated cells into pluripotent stem cells . In addition, SON promotes correct splicing of a particular group of RNAs, including those coding for essential hESC regulators, and thereby helps hESCs to survive in an undifferentiated state. Moreover, the authors showed that silencing of SON induced new transcript isoforms that seemed to be non-functional in hESCs.

T
'/>"/>

Contact: Winnie Lim
limcp2@gis.a-star.edu.sg
65-680-88013
Agency for Science, Technology and Research (A*STAR), Singapore
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Made-in-Singapore H5N1 diagnostic kit -- detects all known strains of H5N1 virus with a single test
2. NUS launches new book on Singapores rainforests and new free digital nature archive
3. Singapore scientists find genes associated with glaucoma, a major cause of eye blindness
4. National Heart Centre Singapore develops worlds first human heart cell model
5. First in the world - Singapore scientists discover genes responsible for cornea blindness
6. Singapore research team identifies new drug target in deadly form of leukemia
7. Less haze in Singapore as the cause becomes clearer and more complex
8. Physiotherapy in Singapore Clinic Urbanrehab Pte Ltd Announces the Opening of an Additional Location
9. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
10. Queens scientists seek vaccine for Pseudomonas infection
11. Scientists produce eye structures from human blood-derived stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 30, 2015 after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... (Land-use intensity and Ecological Engineering Assessment ... based production systems) is organizing a conference, entitled ... which will be held in Banaue, The Philippines ... 21 research institutions from Germany, Vietnam, The Philippines, ...
... Germany: The first report of the diagnostic use of the ... analysed, shows that it can give good results at low cost, ... of the European Society of Human Genetics today (Monday). ... around 20% of 100 cases of patients with intellectual disability (ID) ...
... Nature Medicine shows that boosting a protein ... from otherwise fatal radiation poisoning. Scientists in the ... June 24 say their findings open the potential ... or environmental exposures such as in a nuclear ...
Cached Biology News:Exome sequencing gives cheaper, faster diagnosis in heterogeneous disease 2Exome sequencing gives cheaper, faster diagnosis in heterogeneous disease 3Boosting blood system protein complex protects against radiation toxicity 2Boosting blood system protein complex protects against radiation toxicity 3
(Date:7/28/2015)... , July 28, 2015 Tauriga Sciences, Inc. ... life sciences company, today announced that its stockholders approved ... common stock of the Company from 1,000,000,000 to 2,500,000,000 ... 27, 2015 at the Law Offices of Nixon Peabody ... Special Meeting, there were 480,655,929 shares of common stock ...
(Date:7/28/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ) ... to German life sciences entrepreneurs with a proven ... biotechnology (collectively, the "Optionee"), an option to license ... technology (the "Technology"), including AEZS-120, the most advanced ... to enter a Phase 1 clinical trial. This ...
(Date:7/27/2015)... Tenn. , July 27, 2015  Capella ... care services and one of the largest for-profit ... its parent company and sole stockholder, Capella Holdings, ... Properties Trust, Inc. ("MPT") (NYSE: MPW ) ... The transaction is expected to be finalized during ...
(Date:7/27/2015)... 27, 2015   Inocucor Technologies Inc ., ... accelerators for farmers, has received a notice of ... for its patent application to protect Inocucor consortia ... and enhance yields on farms and in greenhouses. ... live IN-M1 microbial consortium and its fermentation byproducts, ...
Breaking Biology Technology:Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3
... Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ... present a corporate overview of the Company at BioFinance ... The conference will be held at the Toronto Marriott ... the leading investor conference in Canada for the life ...
... Cadence Pharmaceuticals, Inc. (Nasdaq: CADX ) ... investigational product candidate, Acetavance(TM) (intravenous acetaminophen), will be presented ... Medicine (ASRA) 34th Annual Regional Anesthesia Meeting in Phoenix, ... of Hospital Medicine (SHM) Annual Meeting in Chicago, Illinois ...
... skin cells to combat aging and help support healing , ... ... Histogen Aesthetics , a division of Histogen focused on providing unique, ... the launch of the ReGenica™ Rejuvenation System for anti-aging and post-resurfacing. ...
Cached Biology Technology:Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioFinance 2009 2Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences 2Histogen Aesthetics Launches ReGenica Rejuvenation System 2Histogen Aesthetics Launches ReGenica Rejuvenation System 3Histogen Aesthetics Launches ReGenica Rejuvenation System 4
Topoisomerase I, isolated from wheat germ, is an enzyme capable of removing negative supercoils from covalently closed circular DNA (1)....
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
The Proteome Profiler Human Phospho-MAPK Array Kit contains 4 membranes - each spotted in duplicate with 23 different MAPK antibodies....
Mycoplasma tested...
Biology Products: